Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares. The reporting period covers the month of August 2025, with the specific transaction date being August 21, 2025. The filing serves as a disclosure of a share repurchase executed under a pre-existing non-discretionary agreement.
Key Financial Metrics and Transaction Details
The filing details a single day of share repurchase activity executed by Merrill Lynch International on behalf of GSK. The following metrics summarize the transaction:
- Shares Purchased: 238,918 ordinary shares of 31½ pence each.
- Price Range: Lowest price paid was 1,473.00 GBp; highest price paid was 1,492.00 GBp.
- Volume-Weighted Average Price (VWAP): 1,485.14 GBp.
- Trading Venue: All purchases occurred on the London Stock Exchange (XLON). No purchases were made on CBOE Europe venues (CHIX or BATE).
- Program Status: This purchase is part of an existing buyback programme initiated via a non-discretionary agreement on June 4, 2025. Since that date, the company has purchased a total of 25,029,256 ordinary shares.
Material Changes and Capital Structure
Following the August 21 transaction, GSK's capital structure reflects the following updates:
- Treasury Shares Held: 243,163,639 ordinary shares.
- Shares in Issue (excluding Treasury): 4,072,228,095 ordinary shares.
- Total Voting Rights: 4,072,228,095.
- Treasury Share Voting Percentage: The percentage of voting rights attributable to shares held in treasury is 5.97%.
The filing does not provide data on revenue, profit, cash flow, margins, or debt levels, as it is a transaction-specific disclosure rather than a financial results report.
Guidance, Outlook, and Risks
The filing contains no new financial guidance, operational outlook, or management commentary regarding business performance. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially from projections due to risks and uncertainties. These risks are referenced as being described in the "Risk Factors" section of GSK's Annual Report on Form 20-F for 2024 and its Q2 Results for 2025.
Key Facts for Investor Verification
- Verify the total number of shares purchased under the buyback programme since June 4, 2025 (25,029,256 shares).
- Confirm the current percentage of voting rights held in treasury (5.97%) against the total voting rights (4,072,228,095).
- Note that the repurchase was executed via a non-discretionary agreement, meaning the broker acted according to pre-set parameters rather than discretionary judgment on the day of trade.
- Review the referenced 2024 Form 20-F and 2025 Q2 Results for the full context of risk factors mentioned in the cautionary statement.